CMA Recommendations on Canada’s First National Adaptation Strategy: Addressing the health impacts of climate change
https://policybase.cma.ca/link/policy14484

POLICY TYPE  Parliamentary submission
DATE  2022-06-23
TOPICS  Population health, health equity, public health
Health systems, system funding and performance

Documents
CMA Letter to the Council of the Federation regarding the Council of the Federation meeting and Canada’s health funding priorities (health workforce, primary care, labour mobility)
https://policybase.cma.ca/link/policy14486

POLICY TYPE          Parliamentary submission
DATE                 2022-06-22
TOPICS               Health systems, system funding and performance
                      Health human resources

Documents
CMA Recommendations on Vaccine Equity and Intellectual Property
https://policybase.cma.ca/link/policy14476

POLICY TYPE
Parliamentary submission

DATE
2022-05-13

TOPICS
Ethics and medical professionalism
Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents

CMA Recommendations on Vaccine Equity and Intellectual Property
House of Commons Standing Committee on Foreign Affairs and International Development
May 11, 2022
Appearance before the House of Commons Standing Committee on Health

Dr. Katherine Smart
President of the Canadian Medical Association

May 9, 2022

Thank you very much.
Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

https://policybase.cma.ca/link/policy14474

POLICY TYPE  Parliamentary submission

DATE  2022-05-03

TOPICS  Population health, health equity, public health
Ethics and medical professionalism

Documents

Appearance before the Standing Committee on Indigenous and Northern Affairs (INAN): Administration and accessibility of Indigenous Peoples to the Non-Insured Benefits Program

Dr. Alka Lafontaine
President, Canadian Medical Association
May 4, 2022

(Notes and slides available)
Health Human Resource Policy Recommendations: Summary. Briefing to the House of Commons Standing Committee on Health
https://policybase.cma.ca/link/policy14473

POLICY TYPE: Parliamentary submission
DATE: 2022-04-14
TOPICS: Health systems, system funding and performance
Ethics and medical professionalism

Documents
Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

https://policybase.cma.ca/link/policy14472

POLICY TYPE
Parliamentary submission

DATE
2022-03-28

TOPICS
Health human resources
Health systems, system funding and performance

Documents

Appearance before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities

Dr. Katherine Smart
President of the Canadian Medical Association
March 28, 2022

[Signature]
Federal Policy Options to Advance Pan-Canadian Licensure

https://policybase.cma.ca/link/policy14471

POLICY TYPE
Parliamentary submission

DATE
2022-02-22

TOPICS
Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents

[Image of document]
Study on Canada’s Health Workforce
https://policybase.cma.ca/link/policy14469

POLICY TYPE  Parliamentary submission
DATE  2022-02-16
TOPICS  Health systems, system funding and performance
Health human resources
Ethics and medical professionalism

Documents

Appearance before the House of Commons Standing Committee on Health:

Study on Canada’s Health Workforce

DR. J.I. Smart
President of the Canadian Medical Association
February 15, 2022
Deed against doers
Canadian Medical Association input in advance of the World Health Assembly Special Session
https://policybase.cma.ca/link/policy14461

POLICY TYPE  Parliamentary submission
DATE           2021-11-17
TOPICS         Population health, health equity, public health
               Ethics and medical professionalism

Documents
New Criminal Code offence to protect health workers from threats and violence, including online
https://policybase.cma.ca/link/policy14463

POLICY TYPE
Parliamentary submission

DATE
2021-11-16

TOPICS
Population health, health equity, public health
Ethics and medical professionalism

Documents
The Lancet Countdown on Health and Climate Change - Policy brief for Canada, October 2021
https://policybase.cma.ca/link/policy14455

POLICY TYPE: Policy endorsement
DATE: 2021-10-20
TOPICS: Population health, health equity, public health

Documents
São Paulo Declaration on Planetary Health

https://policybase.cma.ca/link/policy14456

POLICY TYPE  Policy endorsement

DATE  2021-10-04

TOPICS  Population health, health equity, public health

Documents

| São Paulo Declaration on Planetary Health
| Planetary Health for all: Avoiding Communities to Achieve the Great Transition

Table of Contents

- Introduction
- Overview
- For All: Agriculture, Food, and Farm Support
- For Air: Pollution, Health, and Sustainability
- For Water: Access, Safety, and Sustainability
- For Energy: Security, Efficiency, and Innovation
- For Health: Access, Equity, and Sustainability
- For Education: Access, Equity, and Sustainability
- For Staff: Healthcare, Education, and Sustainability

Conclusion
Vaccine certificates

https://policybase.cma.ca/link/policy14448

POLICY TYPE  Policy document
DATE  2021-08-21
TOPICS  Population health, health equity, public health
Ethics and medical professionalism

Documents
Mandatory COVID-19 vaccination of health care workers

https://policybase.cma.ca/link/policy14449

POLICY TYPE: Policy document
DATE: 2021-08-21
TOPICS: Health human resources
Population health, health equity, public health

Documents
Global vaccine equity
https://policybase.cma.ca/link/policy14451

POLICY TYPE
Policy document
DATE
2021-08-21
TOPICS
Ethics and medical professionalism
Population health, health equity, public health
Return to school during COVID-19
https://policybase.cma.ca/link/policy14452

POLICY TYPE
Policy document

DATE
2021-08-21

TOPICS
Health care and patient safety
Population health, health equity, public health

Documents
Interchangeability of vaccines (vaccine mixing)
https://policybase.cma.ca/link/policy14453

POLICY TYPE  Policy document
DATE        2021-08-21
TOPICS      Health care and patient safety
Population health, health equity, public health

Documents

Interchangeability of vaccines (vaccine mixing)

Policy position/Recommendations:

1. The CMA recommends that the federal government, in consultation with the provinces, consider the following recommendations for the interchangeability of vaccines:
   - Vaccines should be interchangeable if they are produced by the same manufacturer.
   - If vaccines are produced by different manufacturers, they should be considered interchangeable if they meet the criteria outlined by Health Canada.

2. The CMA supports the development of guidelines for the interchangeability of vaccines that are consistent with international standards and best practices.

3. The CMA recommends that the federal government establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

Interchangeability of vaccines: a summary of considerations

Interchangeability of vaccines is a critical aspect of vaccine policy. It refers to the ability to interchange vaccines from different manufacturers within a given population. Interchangeability is determined by factors such as the similarity of the vaccine formulations, the similarity of the vaccine production processes, and the similarity of the vaccine safety profiles.

Policy implications:

1. The CMA recommends that the federal government, in consultation with the provinces, establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

2. The CMA supports the development of guidelines for the interchangeability of vaccines that are consistent with international standards and best practices.

3. The CMA recommends that the federal government establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

Interchangeability of vaccines: a summary of considerations

Interchangeability of vaccines is a critical aspect of vaccine policy. It refers to the ability to interchange vaccines from different manufacturers within a given population. Interchangeability is determined by factors such as the similarity of the vaccine formulations, the similarity of the vaccine production processes, and the similarity of the vaccine safety profiles.

Policy implications:

1. The CMA recommends that the federal government, in consultation with the provinces, establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

2. The CMA supports the development of guidelines for the interchangeability of vaccines that are consistent with international standards and best practices.

3. The CMA recommends that the federal government establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

Interchangeability of vaccines: a summary of considerations

Interchangeability of vaccines is a critical aspect of vaccine policy. It refers to the ability to interchange vaccines from different manufacturers within a given population. Interchangeability is determined by factors such as the similarity of the vaccine formulations, the similarity of the vaccine production processes, and the similarity of the vaccine safety profiles.

Policy implications:

1. The CMA recommends that the federal government, in consultation with the provinces, establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

2. The CMA supports the development of guidelines for the interchangeability of vaccines that are consistent with international standards and best practices.

3. The CMA recommends that the federal government establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

Interchangeability of vaccines: a summary of considerations

Interchangeability of vaccines is a critical aspect of vaccine policy. It refers to the ability to interchange vaccines from different manufacturers within a given population. Interchangeability is determined by factors such as the similarity of the vaccine formulations, the similarity of the vaccine production processes, and the similarity of the vaccine safety profiles.

Policy implications:

1. The CMA recommends that the federal government, in consultation with the provinces, establish a system for monitoring the interchangeability of vaccines to ensure patient safety.

2. The CMA supports the development of guidelines for the interchangeability of vaccines that are consistent with international standards and best practices.

3. The CMA recommends that the federal government establish a system for monitoring the interchangeability of vaccines to ensure patient safety.